Bactericidal properties of moxifloxacin and post-antibiotic effect

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. B, 1999, Pages 43-49

  Boswell, F J ^a   Andrews, J M ^a   Wise, R ^a   Dalhoff, A ^b  

^a CITY HOSPITAL   (United Kingdom)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ARTICLE; BACTERICIDAL ACTIVITY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; KINETICS; SERUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLINES; SERUM BACTERICIDAL TEST; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0032945878     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
2. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 639-51.
3. Woodcock, J. M., Andrews, J. M., Boswell, A. F., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
4. Rustige, C. & Wiedemann, B. (1991). Pharmacodynamic differences of quinolones towards bacteria with identical MICs. In Program and Abstracts of the Seventeenth International Congress of Chemotherapy, Berlin, Germany, 1991. Poster 651.
5. Dalhoff, A., Matutat, S. & Ullmann, U. (1995). Effect of quinolones against slowly growing bacteria. Chemotherapy 41, 92-9.
6. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Tentative Guideline M26-T. NCCLS, Wayne, PA.
7. Craig, W. A. & Gudmundsson, S. (1991). Postantibiotic effect. In Antibiotics in Laboratory Medicine, 3rd edn (Lorian, V., Ed.), pp. 403-31. Williams & Wilkins, Baltimore, MD.
8. Miles, A. A. & Misra, S. S. (1938). The estimation of the bactericidal power of the blood. Journal of Hygiene 38, 732-40.
9. Grasso, S., Meinardi, G., de Carneti, I. & Tamassia, V. (1978). New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrobial Agents and Chemotherapy 13, 570-6.
10. Bigger, J. W. (1944). The bactericidal action of penicillin on Staphylococcus pyogenes. Irish Journal of Medical Science 227, 533-68.
11. Chin, N.-X. & Neu, H. C. (1987). Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. American Journal of Medicine 82, Suppl. 4A, 58-62.
12. Fantin, B., Ebert, S., Leggett, J., Vogelman, B. & Craig, W. A. (1991). Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. Journal of Antimicrobial Chemotherapy 27, 829-36.
13. Craig, W. A. & Ebert, S. C. (1991). Killing and regrowth of bacteria in vitro: a review. Scandinavian Journal of Infectious Diseases. Supplementum 74, 63-70.
14. Gudmundsson, S., Einarsson, S., Erlendsdottir, H., Moffat, J., Bayer, W. & Craig, W. A. (1993). The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. Journal of Antimicrobial Chemotherapy 31, Suppl. D, 177-91.
15. Dalhoff, A. (1995). Activities of ciprofloxacin and sparfloxacin against S. pneumoniae. Drugs 49, Suppl. 2, 194-60.
16. Hyatt, J. M., Nix, D. E., Stratton, C. W. & Schentag, J. J. (1995). In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1711-6.
17. Barry, A. L., Jones, R. N., Thornsberry, C., Ayers, L. W., Gerlach, E. H. & Sommers, H. M. (1984). Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin and nalidixic acid. Antimicrobial Agents and Chemotherapy 25, 633-7.
18. Maple, P., Brumfitt, W. & Hamilton-Miller, J. M. (1990). A review of the antimicrobial activity of fluoroquinolones. Journal of Chemotherapy 2, 280-94.
19. Eliopoulos, G. M. & Eliopoulos, C. M. (1993). Activity in vitro of the quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 161-93. American Society for Microbiology, Washington, DC.
20. Prosser, B. L. & Beskid, G. (1995). Mullicenter in vitro comparative study of fluoroquinolones against 25, 129 gram-positive and gram-negative clinical isolates. Diagnostic Microbiology and Infectious Disease 21, 33-44.
21. Hoogkamp-Korstanje, J. A. (1997). In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. Journal of Antimicrobial Chemotherapy 40, 427-31.
22. Boswell, F. J., Andrews, J. M. & Wise, R. (1997). Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and post-antibiotic effect. Antimicrobial Agents and Chemotherapy 41, 1377-5.